These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]
7. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis. Dhooghe B; Haaf JB; Noel S; Leal T Expert Opin Investig Drugs; 2016; 25(4):423-36. PubMed ID: 26878157 [TBL] [Abstract][Full Text] [Related]
8. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Bell SC; De Boeck K; Amaral MD Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877 [TBL] [Abstract][Full Text] [Related]
9. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
10. New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators? Davies JC; Martin I Expert Opin Pharmacother; 2018 Aug; 19(12):1327-1336. PubMed ID: 30101632 [TBL] [Abstract][Full Text] [Related]
11. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Merk D; Schubert-Zsilavecz M Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506 [TBL] [Abstract][Full Text] [Related]
18. The future of CFTR modulating therapies for cystic fibrosis. Davies JC Curr Opin Pulm Med; 2015 Nov; 21(6):579-84. PubMed ID: 26390337 [TBL] [Abstract][Full Text] [Related]
19. New and Emerging Treatments for Cystic Fibrosis. Barry PJ; Jones AM Drugs; 2015 Jul; 75(11):1165-75. PubMed ID: 26091951 [TBL] [Abstract][Full Text] [Related]
20. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics. Goralski JL; Davis SD Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]